Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$30.82 USD
-0.69 (-2.19%)
Updated May 17, 2024 04:00 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 421 - 440 ( 718 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
After the Election: Impact to Biotech of a Trump Presidency
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
November and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Near-Term Headwinds Persist but Reacceleration of EXPAREL Sales Expected as New Initiatives Take Hold; Reiterate OUTPERFORM but Reducing PT to $89
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q3 Preview: Symphony Health Q3 EXPAREL Estimate Is About 4% Below Consensus and We Reduced Our Estimates; Reiterate OUTPERFORM but Reducing PT to $93
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
October and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
EXPAREL Launched for Oral Surgery Pain Management; Reiterate OUTPERFORM and $109 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Symphony Health Estimates for Q3 EXPAREL Sales Are Tracking About -7.6% Below Consensus but Seasonal; Reiterate OUTPERFORM and $109 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
September and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 29
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July Symphony Health EXPAREL Estimate ~1.5% Below Consensus but Accelerating Sales per Day; Reiterate OUTPERFORM and $109 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Solid Q2 Beat Consensus--We See Increasing Demand for Opioid Sparing Pain Management Using EXPAREL; Reiterate OUTPERFORM and Increasing PT to $109
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August and Full Year 2016 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L